Reporting Manager
James B. Tananbaum
Symbol
LYEL
Shares outstanding
19,139,684 shares
Disclosed Ownership
1,454,616 shares
Ownership
7.6%
Form type
SCHEDULE 13G/A
Filing time
14 Nov 2025, 16:05:18 UTC
Date of event
30 Sep 2025

Sponsored

Quoteable Key Fact

"Foresite Capital Fund IV, L.P. disclosed 7.6% ownership in Lyell Immunopharma, Inc. Common Stock, par value $0.0001 (LYEL) on 30 Sep 2025."

Quick Takeaways

  • Foresite Capital Fund IV, L.P. filed SCHEDULE 13G/A for Lyell Immunopharma, Inc. Common Stock, par value $0.0001 (LYEL).
  • Disclosed ownership: 7.6%.
  • Date of event: 30 Sep 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 14 Nov 2025, 16:05.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (7)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Foresite Capital Fund IV, L.P. 4.2% 800,339 800,339 0 /s/ James Tananbaum James Tananbaum, Managing Member of the General Partner
Foresite Capital Management IV, LLC 4.2% 800,339 800,339 0 /s/ James Tananbaum James Tananbaum, Managing Member
Foresite Capital Fund V, L.P. 2.5% 477,078 477,078 0 /s/ James Tananbaum James Tananbaum, Managing Member of the General Partner
Foresite Capital Management V, LLC 2.5% 477,078 477,078 0 /s/ James Tananbaum James Tananbaum, Managing Member
Foresite Capital Opportunity Fund V, L.P. 0.9% 177,199 177,199 0 /s/ James Tananbaum James Tananbaum, Managing Member of the General Partner
Foresite Capital Opportunity Management V, LLC 0.9% 177,199 177,199 0 /s/ James Tananbaum James Tananbaum, Managing Member
James B. Tananbaum 7.6% 1,454,616 1,454,616 0 /s/ James Tananbaum James Tananbaum